Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Influenza Drugs market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Influenza Drugs market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Influenza Drugs market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Influenza Drugs products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Influenza Drugs products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Influenza Drugs market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Influenza Drugs development has been the leading industry trend of Influenza Drugs market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Influenza Drugs Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
| Report Attributes |
Details |
| The market size value in 2021 |
USD XX.XX Million |
| CAGR (2021 - 2028) |
XX.XX % |
| The Revenue forecast in 2028 |
USD XX.XX Million |
| Base year for estimation |
2021 |
| Historical data |
2018-2019 |
| Forecast period |
2022-2028 |
| Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
| Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
| Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
| By Type Outlook |
Oseltamivir, Zanamivir, Amantadine, Rimantadine |
| By Application Outlook |
Hospital, Pharmacy, Other |
| Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
| Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
| Key companies profiled |
Roche, Shionogi, Cipla, Sun Pharmaceutical, GlaxoSmithKline, Mitsubishi Chemical, Daiichi Sankyo, ADMA Biologics, Teva, CSL, Sanofi, AstraZeneca, Biondvax, HEC, China Resources Sanjiu, BaiYunShan General Factory (BYS), Livzon Pharm, Northeast Pharm, Others |
| Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Roche
- Shionogi
- Cipla
- Sun Pharmaceutical
- GlaxoSmithKline
- Mitsubishi Chemical
- Daiichi Sankyo
- ADMA Biologics
- Teva
- CSL
- Sanofi
- AstraZeneca
- Biondvax
- HEC
- China Resources Sanjiu
- BaiYunShan General Factory (BYS)
- Livzon Pharm
- Northeast Pharm
- Others
Influenza Drugs Market, By Type
- Oseltamivir
- Zanamivir
- Amantadine
- Rimantadine
Influenza Drugs Market, By Application
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Global Influenza Drugs Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 Influenza Drugs Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Oseltamivir Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Zanamivir Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.3 Amantadine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.4 Rimantadine Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific Influenza Drugs Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America Influenza Drugs Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe Influenza Drugs Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America Influenza Drugs Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa Influenza Drugs Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World Influenza Drugs Market Assessment by Type
8.1 Asia Pacific Influenza Drugs Market Assessment by Application (Consumption and Market Share)
8.2 North America Influenza Drugs Market Assessment by Application (Consumption and Market Share)
8.3 Europe Influenza Drugs Market Assessment by Application (Consumption and Market Share)
8.4 South America Influenza Drugs Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa Influenza Drugs Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Roche
9.1.1 Roche Profiles
9.1.2 Roche Product Portfolio
9.1.3 Roche Influenza Drugs Business Performance
9.1.4 Roche Influenza Drugs Business Development and Market Status
9.2 Shionogi
9.2.1 Shionogi Profiles
9.2.2 Shionogi Product Portfolio
9.2.3 Shionogi Influenza Drugs Business Performance
9.2.4 Shionogi Influenza Drugs Business Development and Market Status
9.3 Cipla
9.3.1 Cipla Profiles
9.3.2 Cipla Product Portfolio
9.3.3 Cipla Influenza Drugs Business Performance
9.3.4 Cipla Influenza Drugs Business Development and Market Status
9.4 Sun Pharmaceutical
9.4.1 Sun Pharmaceutical Profiles
9.4.2 Sun Pharmaceutical Product Portfolio
9.4.3 Sun Pharmaceutical Influenza Drugs Business Performance
9.4.4 Sun Pharmaceutical Influenza Drugs Business Development and Market Status
9.5 GlaxoSmithKline
9.5.1 GlaxoSmithKline Profiles
9.5.2 GlaxoSmithKline Product Portfolio
9.5.3 GlaxoSmithKline Influenza Drugs Business Performance
9.5.4 GlaxoSmithKline Influenza Drugs Business Development and Market Status
9.6 Mitsubishi Chemical
9.6.1 Mitsubishi Chemical Profiles
9.6.2 Mitsubishi Chemical Product Portfolio
9.6.3 Mitsubishi Chemical Influenza Drugs Business Performance
9.6.4 Mitsubishi Chemical Influenza Drugs Business Development and Market Status
9.7 Daiichi Sankyo
9.7.1 Daiichi Sankyo Profiles
9.7.2 Daiichi Sankyo Product Portfolio
9.7.3 Daiichi Sankyo Influenza Drugs Business Performance
9.7.4 Daiichi Sankyo Influenza Drugs Business Development and Market Status
9.8 ADMA Biologics
9.8.1 ADMA Biologics Profiles
9.8.2 ADMA Biologics Product Portfolio
9.8.3 ADMA Biologics Influenza Drugs Business Performance
9.8.4 ADMA Biologics Influenza Drugs Business Development and Market Status
9.9 Teva
9.9.1 Teva Profiles
9.9.2 Teva Product Portfolio
9.9.3 Teva Influenza Drugs Business Performance
9.9.4 Teva Influenza Drugs Business Development and Market Status
9.10 CSL
9.10.1 CSL Profiles
9.10.2 CSL Product Portfolio
9.10.3 CSL Influenza Drugs Business Performance
9.10.4 CSL Influenza Drugs Business Development and Market Status
9.11 Sanofi
9.12 AstraZeneca
9.13 Biondvax
9.14 HEC
9.15 China Resources Sanjiu
9.16 BaiYunShan General Factory (BYS)
9.17 Livzon Pharm
9.18 Northeast Pharm
9.19 Others
10 World Influenza Drugs Market Assessment by Players
10.1 Global Influenza Drugs Sales (K Units) and Market Share by Players 2014-2020
10.2 Global Influenza Drugs Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global Influenza Drugs Price (USD/Unit) of Players 2014-2020
10.4 Global Influenza Drugs Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America Influenza Drugs Sales Assessment of Players 2014-2020
11.1.2 North America Influenza Drugs Revenue Assessment of Players 2014-2020
11.1.3 North America Influenza Drugs Price Assessment of Players 2014-2020
11.1.4 North America Influenza Drugs Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe Influenza Drugs Sales Assessment of Players 2014-2020
11.2.2 Europe Influenza Drugs Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe Influenza Drugs Price Assessment of Players 2014-2020
11.2.4 Europe Influenza Drugs Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific Influenza Drugs Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific Influenza Drugs Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific Influenza Drugs Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific Influenza Drugs Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America Influenza Drugs Sales Assessment of Players 2014-2020
11.4.2 South America Influenza Drugs Revenue Assessment of Players 2014-2020
11.4.3 South America Influenza Drugs Price Assessment of Players 2014-2020
11.4.4 South America Influenza Drugs Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa Influenza Drugs Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa Influenza Drugs Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa Influenza Drugs Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa Influenza Drugs Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific Influenza Drugs Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific Influenza Drugs Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific Influenza Drugs Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America Influenza Drugs Sales by Countries/Regions 2014-2020
12.2.2 North America Influenza Drugs Revenue by Countries/Regions 2014-2020
12.2.3 North America Influenza Drugs Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe Influenza Drugs Sales by Countries/Regions 2014-2020
12.3.2 Europe Influenza Drugs Revenue by Countries/Regions 2014-2020
12.3.3 Europe Influenza Drugs Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America Influenza Drugs Sales by Countries/Regions 2014-2020
12.4.2 South America Influenza Drugs Revenue by Countries/Regions 2014-2020
12.4.3 South America Influenza Drugs Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa Influenza Drugs Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa Influenza Drugs Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa Influenza Drugs Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World Influenza Drugs Sales & Revenue Forecast 2021-2026
14.1 World Influenza Drugs Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World Influenza DrugsSales and Market Share by Regions
14.1.2 World Influenza DrugsRevenue and Market Share by Regions
15 Asia Influenza Drugs Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Oseltamivir
15.1.2 Zanamivir
15.1.3 Amantadine
15.1.4 Rimantadine
15.2 Consumption Forecast by Application, 2021-2026
16 North America Influenza Drugs Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Oseltamivir
16.1.2 Zanamivir
16.1.3 Amantadine
16.1.4 Rimantadine
16.2 Consumption Forecast by Application, 2021-2026
17 Europe Influenza Drugs Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Oseltamivir
17.1.2 Zanamivir
17.1.3 Amantadine
17.1.4 Rimantadine
17.2 Consumption Forecast by Application, 2021-2026
18 South America Influenza Drugs Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Oseltamivir
18.1.2 Zanamivir
18.1.3 Amantadine
18.1.4 Rimantadine
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa Influenza Drugs Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Oseltamivir
19.1.2 Zanamivir
19.1.3 Amantadine
19.1.4 Rimantadine
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global Influenza Drugs Price (USD/Unit) Trend 2021-2026
20.2 Global Influenza Drugs Gross Profit Trend 2021-2026
21 Conclusion
